Researchers have discovered how diseased cells can be transformed into healthy cells

Spanish and Israeli scientists conducted an experiment in vitro aims to alter the genetic nature of cancer cells to make them healthy. A potentially major advance in the fight against cancer.

Will it soon be possible to cure cancer by reversing the disease’s biological process of turning healthy cells into malignant cells? It is definitely a new hope made possible by the results of a research program carried out in collaboration between Spanish and Israeli scientists.

In an article dedicated to her work, published on the journal’s website Naturethe researchers claim to have succeeded disrupt the genetic nature of cancer cells by making chemical changes to their messenger RNAa technique called epigeneticswhereby the same DNA can be used differently from one cell to another.

Can you “modify” cancer cells?

In other words, we are facing a potential revolution in the fight against cancer. Because although the molecular changes responsible for the transformation of healthy tissue into tumorous tissue have been studied extensively over the last few decades, until now scientists knew very little about the reverse process that can lead to a cancer cell becoming healthy again.

The researchers focused on this cellular transformation by developing a model in vitro in which leukemia cells were treated to turn into a type of harmless immune cell called macrophages.

In their investigations, the scientists observed a change in the genetic nature of these cells after a major revision of the chemical changes occurring to their messenger RNA. These changes mainly affected the distribution of a so-called epigenetic marker methylated adenine.

A new approach to curing leukemia?

The results are promising enough for the research team who believe this research should be further explored as a new approach to tackling leukemia, which has half a million patients diagnosed worldwide every year. However, the program has not yet been tested on patients.

“The first preclinical drugs against this target have already been developed in experimental models of malignant blood diseases. With this, we provide another reason why these new drugs could be useful in cancer therapy, especially in leukemia and lymphoma.”closes dr Manel Esteller, who heads the Josep Carreras Leukemia Research Institute at the University of Barcelona.

Leave a Comment